ATRX and cancer: In work described by Kovatcheva et al a new molecular mechanism wherein MDM2 and ATRX determine cell fate following CDK4/6 inhibition in cancer cells derived from several distinct cancer etiologies such as well-differentiated and dedifferentiated liposarcoma (WD/DDLS), lung cancer, and glioma (6).